scholarly article | Q13442814 |
P356 | DOI | 10.1007/S40256-015-0157-9 |
P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s40256-015-0157-9 |
P698 | PubMed publication ID | 26749408 |
P2093 | author name string | Zhigang Yu | |
Donglu Zhang | |||
Charles Frost | |||
Frank LaCreta | |||
Wonkyung Byon | |||
Clapton Dias | |||
Jessie Wang | |||
Andrew Shenker | |||
Rebecca A Boyd | |||
Blisse Vakkalagadda | |||
P2860 | cites work | Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...] | Q27648707 |
Membrane transporters in drug development | Q29616802 | ||
Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
Apixaban metabolism and pharmacokinetics after oral administration to humans | Q33373622 | ||
Apixaban or enoxaparin for thromboprophylaxis after knee replacement | Q34018819 | ||
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial | Q34102430 | ||
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement | Q34156023 | ||
Apixaban in patients with atrial fibrillation | Q34163710 | ||
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects | Q34285711 | ||
The drug efflux-metabolism alliance: biochemical aspects. | Q34384318 | ||
Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery | Q34413003 | ||
Pharmacokinetic interactions with rifampicin : clinical relevance | Q35185727 | ||
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor | Q35557449 | ||
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes | Q35608569 | ||
Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban | Q35666219 | ||
Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping | Q36922212 | ||
Pharmacokinetics and metabolic drug interactions. | Q37230205 | ||
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects | Q37369329 | ||
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects | Q37653181 | ||
Characterization of efflux transporters involved in distribution and disposition of apixaban. | Q39199496 | ||
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin | Q40851439 | ||
In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | Q43235385 | ||
Oral apixaban for the treatment of acute venous thromboembolism | Q43741993 | ||
Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. | Q46023319 | ||
Sulfation of o-demethyl apixaban: enzyme identification and species comparison | Q46170713 | ||
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies | Q46722053 | ||
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. | Q51521480 | ||
Tissue distribution and elimination of [14C]apixaban in rats. | Q51533087 | ||
General derivation of the equation for time to reach a certain fraction of steady state. | Q52434488 | ||
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. | Q52838335 | ||
P433 | issue | 2 | |
P921 | main subject | pharmacokinetics | Q323936 |
apixaban | Q414462 | ||
rifampicin | Q422652 | ||
P304 | page(s) | 119-127 | |
P577 | publication date | 2016-04-01 | |
P1433 | published in | American journal of cardiovascular drugs | Q2555367 |
P1476 | title | Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. | |
P478 | volume | 16 |
Q90160421 | A Simple Methodology to Differentiate Changes in Bioavailability from Changes in Clearance Following Oral Dosing of Metabolized Drugs |
Q92028447 | Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review |
Q38960858 | Apixaban: A Review in Venous Thromboembolism |
Q90348789 | Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care |
Q38616215 | Drug interactions with new oral anticoagulants in elderly patients |
Q90211829 | Drug-Drug Interactions with Direct Oral Anticoagulants |
Q38830358 | Drug-drug interactions of non-vitamin K oral anticoagulants |
Q36797336 | Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor |
Q37519054 | New oral anticoagulants and the cancer patient. |
Q38194842 | Oral anticoagulants for Asian patients with atrial fibrillation |
Q41083353 | Pharmacokinetics of apixaban |
Q64977733 | Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. |
Q33729811 | Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism |
Q49850586 | Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. |
Q91812150 | Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges |
Q37669187 | The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
Q53622758 | The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al. |
Q26828439 | The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery |
Search more.